KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to -$5.8 million.

  • Arbutus Biopharma's Free Cash Flow rose 7194.73% to -$5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.4 million, marking a year-over-year increase of 3693.53%. This contributed to the annual value of -$65.0 million for FY2024, which is 2520.24% up from last year.
  • Arbutus Biopharma's Free Cash Flow amounted to -$5.8 million in Q3 2025, which was up 7194.73% from -$15.7 million recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Free Cash Flow peaked at $20.5 million during Q1 2022, and registered a low of -$27.4 million during Q1 2023.
  • In the last 5 years, Arbutus Biopharma's Free Cash Flow had a median value of -$17.3 million in 2023 and averaged -$15.3 million.
  • As far as peak fluctuations go, Arbutus Biopharma's Free Cash Flow skyrocketed by 21426.03% in 2022, and later plummeted by 23345.99% in 2023.
  • Arbutus Biopharma's Free Cash Flow (Quarter) stood at -$19.7 million in 2021, then grew by 12.92% to -$17.1 million in 2022, then decreased by 0.98% to -$17.3 million in 2023, then surged by 39.85% to -$10.4 million in 2024, then soared by 44.07% to -$5.8 million in 2025.
  • Its Free Cash Flow stands at -$5.8 million for Q3 2025, versus -$15.7 million for Q2 2025 and -$13.4 million for Q1 2025.